CA-VELODYNE-LIDAR,-INC.
Velodyne Lidar, Inc. today announced it has joined the Intelligent Transportation Society of America (ITS America) to promote the benefits of autonomous vehicles and intelligent transportation infrastructure. Velodyne is the first lidar technology company to become part of this influential group. ITS America members are at the forefront of driving progress in autonomous vehicles and smart city solutions to help save lives, improve mobility and promote sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200828005057/en/
Velodyne’s lidar sensors can be used in a variety of Intelligent Transportation Systems to measure and monitor conditions in areas such as pedestrian safety, vehicle traffic and parking space management, and more. They can collect reliable, detailed traffic data about road users, including vehicles, pedestrians and bicyclists, while preserving anonymity. Velodyne’s lidar sensors do not identify individuals’ facial characteristics, a growing requirement for civic applications. In addition to transportation systems, Velodyne’s lidar sensors have a strong presence in autonomous vehicles and advanced driver assistance systems (ADAS).
Velodyne has a long-standing commitment to fostering understanding of the safety and mobility benefits of autonomous vehicles and intelligent infrastructure to consumer, business, government, public safety and community audiences. These efforts include Velodyne’s World Safety Summit on Autonomous Technology . The event has sparked collaborative work to advance solutions for rolling out autonomy and ADAS with the goal of improving safety on the roadways. Velodyne also partners with Mothers Against Drunk Driving (MADD) on public education about improving safety on roadways.
Velodyne’s lidar sensors are used in a rich ecosystem of customers and applications, which is highlighted in the Automated with Velodyne program. Partners in the program provide solutions for smart city, infrastructure, autonomous vehicles and more. Within the program, Velodyne is working to advance research in transportation infrastructure, partnering with University of Nevada, Reno . The university’s Nevada Center for Applied Research, working in conjunction with the Nevada DOT and Nevada Governor’s Office of Economic Development , is using Velodyne’s sensors in its Intelligent Mobility initiative. Velodyne is also partnering with automotive OEMs, and robotaxi and autonomous shuttle companies to enable safe and efficient transportation options for cities. For instance, Voyage has built the technology and services to bring autonomous transportation to those who need it, beginning in retirement communities.
“Lidar is a foundational technology that will help drive intelligent mobility in smart city applications and in vehicles on our roadways,” said Shailen Bhatt, President & CEO, ITS America. “Velodyne has demonstrated a strong commitment and great skills in advancing public knowledge about lidar and how autonomous technology can greatly improve transportation. We welcome their contributions in helping ITS America promote intelligent transportation technologies.”
“Velodyne Lidar is strongly aligned with the ITS America mission to improve mobility, advance safety on the roadways, and increase efficiency in our communities,” said Sally Frykman, VP of Communications, Velodyne Lidar. “We envision companies and government organizations will use Velodyne’s lidar sensors to enable a new generation of smart infrastructure through data collection and the deployment of autonomous vehicles.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized VELARRAY™, and the groundbreaking software for driver assistance, Vella™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200828005057/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom